
Telix Pharmaceuticals upsizes convertible bond offering to $600m
Telix Pharmaceuticals has upsized its convertible bond offering to $600m after strong institutional demand, pricing the five-year notes at a 1.5% coupon to fund a major repurchase of its existing 2029 paper.
6 hours ago



.jpg&c=1&h=180&q=80&v=20260415&w=320)





.jpg&c=1&h=310&q=80&v=20260415&w=552)

